This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement

12/02/14 - 04:34 PM EST

Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement Puma Biotechnology is pushing back an approval filing for its breast cancer drug neratinib into 2016 -- almost a one year delay.

READ FULL POST

Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study

12/01/14 - 11:37 AM EST

Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.

READ FULL POST

Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing

11/24/14 - 09:39 AM EST

Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.

READ FULL POST

Royalty Pharma's $3.3 Billion Transaction is Bullish for Vertex Pharma

11/19/14 - 01:25 PM EST

Royalty Pharma's $3.3 Billion Transaction is Bullish for Vertex Pharma The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.

READ FULL POST

NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study

11/18/14 - 10:16 AM EST

NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study Using stem cells to repair damaged hearts is a great story, but proof remains elusive.

READ FULL POST

Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson

11/13/14 - 04:34 PM EST

Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson J&J is paying $35 million upfront to Geron for rights to the drug.

READ FULL POST

Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting

11/10/14 - 10:40 AM EST

Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'

READ FULL POST

Update: New Patient Receiving BlueBird Gene Therapy Responding More Slowly

11/06/14 - 11:31 AM EST

Update: New Patient Receiving BlueBird Gene Therapy Responding More Slowly The new clinical data on Bluebird's gene therapy are contained in a just-released abstract ahead of next month's American Society of Hematology annual meeting.

READ FULL POST

Epizyme Shares Weak on Disappointing Leukemia Drug Study Results

11/06/14 - 11:12 AM EST

Epizyme Shares Weak on Disappointing Leukemia Drug Study Results New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.

READ FULL POST

After A Long Year, an Update on Geron's Myelofibrosis Drug Is Disclosed

11/06/14 - 09:57 AM EST

After A Long Year, an Update on Geron's Myelofibrosis Drug Is Disclosed The new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Adam's Tweets

Top Rated Stocks Top Rated Funds Top Rated ETFs